The Innovative Medicines Initiative (IMI) is globally recognized as a pioneer of open innovation and an attractive model for successful public-private partnerships (PPPs) in research. A partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), our goal is to improve health by speeding up the development of innovative medicines, particularly in areas where there is an unmet medical or social need. We do this by supporting collaborative projects that bring together all key groups involved in life science research and related sectors. We also strive to take advantage of technological convergence in health, for example through innovative digital solutions. Through our projects, we are finding solutions to the most pressing medical burdens of our time, including antimicrobial resistance, dementia, and diabetes. Eligible universities, small companies, biotechs, patient groups and regulatory bodies receive funding to support their participation in our projects. We also offer large companies and organizations the opportunity to invest in our projects and become IMI Associated Partners. Associated Partners enjoy benefits such as access to complementary skills, expertise, technology and data; the opportunity to share knowledge and risks in a non-competitive space; and the more efficient use of resources. ** Find us in the BIO education program ** Getting to grips with data quality issues through international neuroscience initiatives (Tuesday 4 June, 14:00 | Room 116 | Session ID: 503503). Building a brighter future for children: How will large pediatric trial networks help to deliver safe, effective medicines? (Wednesday 5 June, 16:15 | Room 111AB | Session ID: 503213).